CV Therapeutics to Announce 2004 Second Quarter Financial Results on Thursday, July 29, 2004
July 22 2004 - 8:00AM
PR Newswire (US)
CV Therapeutics to Announce 2004 Second Quarter Financial Results
on Thursday, July 29, 2004 PALO ALTO, Calif., July 22
/PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (NASDAQ:CVTX) today
announced that it will release second quarter financial results for
2004 after the market closes on Thursday, June 29, 2004. Company
management will webcast a conference call at 5:30 p.m. EDT, 2:30
p.m. PDT, on the company's website. To access the live webcast,
please log on to the company's website at http://www.cvt.com/ and
go to the Investor Information section. Alternatively, domestic
callers may participate in the conference call by dialing
888-370-6121, and international callers may participate in the
conference call by dialing 706-679-7163. Webcast and telephone
replays of the conference call will be available approximately two
hours after the completion of the call through Thursday, August 5,
2004. Domestic callers can access the replay by dialing
800-642-1687, and international callers can access the replay by
dialing 706-645-9291; the PIN access number is 8816703. About CV
Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto,
California, is a biopharmaceutical company focused on applying
molecular cardiology to the discovery, development and
commercialization of novel, small molecule drugs for the treatment
of cardiovascular diseases. CV Therapeutics currently has four
compounds in clinical development. CV Therapeutics has received an
approvable letter relating to its NDA for Ranexa for the potential
treatment of chronic angina, and has submitted an application for
the approval of ranolazine for the potential treatment of chronic
angina to the European Medicines Agency. Regadenoson, a selective
A2A-adenosine receptor agonist, is being developed for potential
use as a pharmacologic stress agent in cardiac perfusion imaging
studies. Tecadenoson, an A1-adenosine receptor agonist, is being
developed for the potential reduction of rapid heart rate during
atrial arrhythmias. Adentri(TM), an A1-adenosine receptor
antagonist for the potential treatment of heart failure, is being
developed by Biogen Idec Inc. For more information, please visit CV
Therapeutics' website at http://www.cvt.com/. CV Therapeutics is a
development-stage company. None of the company's products have been
approved for marketing by the FDA or any foreign regulatory
authorities. Any products of the company discussed here are
currently under investigation in clinical trials subject to United
States Investigational New Drug applications, and as applicable,
appropriate clinical trial applications to regulatory authorities
outside the United States. DATASOURCE: CV Therapeutics, Inc.
CONTACT: investors, Dan Spiegelman, SVP & Chief Financial
Officer, +1- 650-384-8509, or Christopher Chai, Treasurer &
Executive Director, Investor Relations, +1-650-384-8560, or media,
John Bluth, Senior Director, Corporate Communications,
+1-650-384-8850, all of CV Therapeutics, Inc. Web site:
http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024